Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...

China’s Ascletis Pharma has announced positive topline results from a US Phase II, 24-week study for its subcutaneous (SC) depot formulations of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 ...

A new study published in the journal of BMC Nephrology showed that subcutaneous and intravenous epoetin showed similar ...

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts;Received written FDA Type C meeting minutes ...

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with ...

AbbVie Inc. (NYSE: ABBV ) is one of the best undervalued stocks to invest in right now.

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Hylenex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ...

The funds will be used for research and development (R&D), working capital, and investments in good manufacturing practice (GMP) facilities. Inventage Lab is pushing to commercialize its long-acting ...

Learn more about whether Halozyme Therapeutics, Inc. or Tango Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.

Johnson & Johnson JNJ announced that it has submitted a type II variation application to the European Medicines Agency (EMA) seeking approval for the expanded use of Tecvayli (teclistamab). The ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...